Michael Thirman to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Michael Thirman has written about Drug Resistance, Neoplasm.
Connection Strength
0.187
-
Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):737-749.
Score: 0.095
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.040
-
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. 2019 08; 60(8):1972-1977.
Score: 0.028
-
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
Score: 0.024